
Nuvalent (NUVL) Stock Forecast & Price Target
Nuvalent (NUVL) Analyst Ratings
Bulls say
Nuvalent Inc's robust clinical data for its product candidates indicates strong efficacy and a favorable tolerability profile, particularly in a large safety population of 432 patients. The company's therapies, especially NVL-520 and NVL-655, demonstrate promising durable central nervous system (CNS) activity, with landmark overall response rates (ORRs) at 96% for both 6- and 12-month durations. These factors suggest a significant potential for market uptake, particularly in the ROS1-positive non-small cell lung cancer segment upon the anticipated approval of zidesamtinib in 2026.
Bears say
Nuvalent Inc faces significant near-term risks that contribute to a negative outlook on its stock, primarily linked to the potential for poorer-than-expected clinical results for its key product candidates, NVL-520 and NVL-655. Such adverse outcomes could necessitate downward revisions in market penetration projections, lead to higher discount rates, and extend the anticipated timelines for potential drug approvals. Additionally, the company confronts competitive threats from superior products and regulatory challenges, particularly regarding its ability to secure favorable reimbursement terms upon commercialization.
This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.
Nuvalent (NUVL) Analyst Forecast & Price Prediction
Start investing in Nuvalent (NUVL)
Order type
Buy in
Order amount
Est. shares
0 shares